Hajime Kaga1, Atsushi Komatsuda2, Soh Yamamoto3, Tadashi Kikuchi4, Mika Kamata5, Akiko Sato5, Masafumi Odaka5, Shin-Ichi Yokota3, Naoto Takahashi1, Hideki Wakui5. 1. Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan. 2. Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan. komatsud@med.akita-u.ac.jp. 3. Department of Microbiology, Sapporo Medical University School of Medicine, Sapporo City, Japan. 4. Technical Support & Marketing Section, Sales Department, Cosmic Corporation, Tokyo, Japan. 5. Department of Life Science, Akita University Graduate School of Engineering Science, Akita City, Japan.
Abstract
BACKGROUND: The prevalence of antibodies against M-type anti-phospholipase A2 receptor (PLA2R) was reported to be ~ 70-80% in early studies on idiopathic membranous nephropathy (iMN) cohorts from Western countries, China, and Korea, and ~ 50% in recent studies on two Japanese iMN cohorts. METHODS: We developed an in-house enzyme-linked immunosorbent assay (ELISA) for the detection of anti-PLA2R antibodies, and examined sera from 217 patients with iMN, 22 patients with secondary MN (sMN), and 50 healthy individuals. All patients and healthy individuals were Japanese. The relationships between levels of anti-PLA2R antibodies and clinical parameters were analyzed. Serum samples were also tested using a standardized commercial ELISA (Euroimmun, Germany). RESULTS: In our ELISA, OD values greater than the mean + 3 standard deviation of healthy subjects were considered to be positive for anti-PLA2R antibodies. Of the patients with iMN, 33.6% (73/217) were positive, but all sMN patients were negative. Our ELISA and the Euroimmun ELISA had a high concordance (93.5%). The proportion of patients with nephrotic syndrome was significantly higher in anti-PLA2R antibody-positive patients than in antibody-negative patients (65.8 vs. 37.5%, P < 0.001). Levels of anti-PLA2R antibodies were significantly correlated with levels of urinary protein and serum albumin (P = 0.004 and P < 0.001, respectively). CONCLUSIONS: The prevalence of anti-PLA2R antibodies in our Japanese iMN cohort was lower than that in the previous studies from other countries and other Japanese institutes. The low prevalence of antibodies may be related with the characteristics of enrolled patients with mild proteinuria and undetectable antibody levels.
BACKGROUND: The prevalence of antibodies against M-type anti-phospholipase A2 receptor (PLA2R) was reported to be ~ 70-80% in early studies on idiopathic membranous nephropathy (iMN) cohorts from Western countries, China, and Korea, and ~ 50% in recent studies on two Japanese iMN cohorts. METHODS: We developed an in-house enzyme-linked immunosorbent assay (ELISA) for the detection of anti-PLA2R antibodies, and examined sera from 217 patients with iMN, 22 patients with secondary MN (sMN), and 50 healthy individuals. All patients and healthy individuals were Japanese. The relationships between levels of anti-PLA2R antibodies and clinical parameters were analyzed. Serum samples were also tested using a standardized commercial ELISA (Euroimmun, Germany). RESULTS: In our ELISA, OD values greater than the mean + 3 standard deviation of healthy subjects were considered to be positive for anti-PLA2R antibodies. Of the patients with iMN, 33.6% (73/217) were positive, but all sMNpatients were negative. Our ELISA and the Euroimmun ELISA had a high concordance (93.5%). The proportion of patients with nephrotic syndrome was significantly higher in anti-PLA2R antibody-positive patients than in antibody-negative patients (65.8 vs. 37.5%, P < 0.001). Levels of anti-PLA2R antibodies were significantly correlated with levels of urinary protein and serum albumin (P = 0.004 and P < 0.001, respectively). CONCLUSIONS: The prevalence of anti-PLA2R antibodies in our Japanese iMN cohort was lower than that in the previous studies from other countries and other Japanese institutes. The low prevalence of antibodies may be related with the characteristics of enrolled patients with mild proteinuria and undetectable antibody levels.
Authors: Yang Gyun Kim; Young-Wook Choi; Se-Yun Kim; Ju Young Moon; Chun-Gyoo Ihm; Tae Won Lee; Kyung-Hwan Jeong; Seung Hee Yang; Yon Su Kim; Yun Jung Oh; Sang Ho Lee Journal: Am J Nephrol Date: 2015-10-20 Impact factor: 3.754
Authors: Sjoerd A M E G Timmermans; Jan G M C Damoiseaux; Petra T J Heerings-Rewinkel; Rivka Ayalon; Laurence H Beck; Wolfgang Schlumberger; David J Salant; Pieter van Paassen; Jan Willem Cohen Tervaert Journal: Am J Clin Pathol Date: 2014-07 Impact factor: 2.493
Authors: Durga Kanigicherla; Jennet Gummadova; Edward A McKenzie; Stephen A Roberts; Shelley Harris; Milind Nikam; Kay Poulton; Lorna McWilliam; Colin D Short; Michael Venning; Paul E Brenchley Journal: Kidney Int Date: 2013-01-30 Impact factor: 10.612
Authors: Astrid Behnert; Marvin J Fritzler; Beina Teng; Meifeng Zhang; Frank Bollig; Hermann Haller; Andrej Skoberne; Michael Mahler; Mario Schiffer Journal: PLoS One Date: 2013-04-29 Impact factor: 3.240
Authors: Astrid Behnert; Mario Schiffer; Janina Müller-Deile; Laurence H Beck; Michael Mahler; Marvin J Fritzler Journal: J Immunol Res Date: 2014-04-09 Impact factor: 4.818